EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms

Fei Li, Zaosong Zheng, Wei Chen, Dongqing Li, Henghui Zhang, Yuanchao Zhu, Qixin Mo, Xinlei Zhao, Qin Fan, Fan Deng, Conghui Han, Wanlong Tan

Drug Resistance Updates · 2023-05 · 68 · 100938

DOI: 10.1016/j.drup.2023.100938 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Resistance Updates, 2023-05. Verfasst von Fei Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 213-mal zitiert (Crossref) und nennt 150 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bladder cancer is one of the most common malignancies in the world. Cisplatin is one of the most potent and widely used anticancer drugs and has been employed in several malignancies. Cisplatin-based combination chemotherapies have become important adjuvant therapies for bladder cancer patients. Cisplatin-based treatment often results in the development of chemoresistance, leading to therapeutic failure and limiting its application and effectiveness in bladder cancer. To develop improved and more effective cancer therapy, research has been conducted to elucidate the underlying mechanism of cisplatin resistance. Epigenetic modifications have been demonstrated involved in drug resistance to chemotherapy, and epigenetic biomarkers, such as urine tumor DNA methylation assay, have been applied in patients screening or monitoring. Here, we provide a systematic description of epigenetic mechanisms, including DNA methylation, noncoding RNA regulation, m6A modification and posttranslational modifications, related to cisplatin resistance in bladder cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsAntineoplastic AgentsHumansCisplatinDrug Resistance, NeoplasmEpigenesis, GeneticMethylationCell Line, Tumor

Stichwörter der Autor:innen

Bladder cancerCisplatin resistanceClinical significanceEpigenetic mechanisms

Substanzen

CisplatinAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
  • Department of Urology, Institute of Precision Medicine, Zigong Forth People's Hospital, Zigong, Sichuan, China.
  • School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong, China.
  • Department of Cell Biology, School of Basic Medical Science, Southern Medical University, Guangzhou, Guangdong, China.
  • Department of Urology, Xuzhou Clinical School of Xuzhou Medical University, Jiangsu, China. Electronic address: hanchdoctor@st.btbu.edu.cn.
  • Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China. Electronic address: twl@smu.edu.cn.

Zitieren

APA

Li, F., Zheng, Z., Chen, W., Li, D., Zhang, H., Zhu, Y., Mo, Q., Zhao, X., Fan, Q., Deng, F., Han, C., & Tan, W. (2023). Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms. Drug Resistance Updates, 68, 100938. https://doi.org/10.1016/j.drup.2023.100938

Vancouver

Li F, Zheng Z, Chen W, Li D, Zhang H, Zhu Y, et al. Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms. Drug Resistance Updates. 2023;68:100938. doi:10.1016/j.drup.2023.100938

BibTeX
@article{Li2023,
  author = {Li, Fei and Zheng, Zaosong and Chen, Wei and Li, Dongqing and Zhang, Henghui and Zhu, Yuanchao and Mo, Qixin and Zhao, Xinlei and Fan, Qin and Deng, Fan and Han, Conghui and Tan, Wanlong},
  title = {Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms},
  journal = {Drug Resistance Updates},
  year = {2023},
  volume = {68},
  pages = {100938},
  doi = {10.1016/j.drup.2023.100938}
}
Kostenlos starten →